Image source: Canva The California Institute for Regenerative Medicine (CIRM) recently awarded $8 million to Rochelle Emery, MD, at Senti Bio to advance a clinical trial for a novel therapy targeting two forms of blood cancer, acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). About AML and MDS Both cancers have a five-year survival rate … Continue reading CIRM Supports Groundbreaking Gene Therapy for AML and MDS
MDS
Friday Round Up
Here’s a look at a couple of stories that caught our eye this week: Jasper Therapeutics has had a busy couple of weeks. Recently they announced data from their Phase 1 clinical trial treating people with Myelodysplastic syndromes (MDS). This is a group of disorders in which immature blood-forming cells in the bone marrow become … Continue reading Friday Round Up
CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
Mark Chao, M.D., Ph.D., cofounder of Forty Seven, Inc. and current VP of oncology clinical research at Gilead Sciences An antibody therapeutic, magrolimab, being tested for myelodysplastic syndrome (MDS), a group of cancers in which the bone marrow does not produce enough healthy blood cells , was granted breakthrough therapy designation with the Food and Drug Administration … Continue reading CIRM-funded treatment for cancer granted FDA breakthrough therapy designation
CIRM funded clinical trial shows promising results for patients with blood cancers
An illustration of a macrophage, a vital part of the immune system, engulfing and destroying a cancer cell. Antibody 5F9 blocks a "don't eat me" signal emitted from cancer cells. Courtesy of Forty Seven, Inc. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both types of blood cancers that can be difficult to treat. CIRM … Continue reading CIRM funded clinical trial shows promising results for patients with blood cancers